The latest update is out from Bioxytran ( (BIXT) ).
Bioxytran, Inc. is making strategic moves in the financial market with its acquisition of NDPD Pharma, Inc., a company holding valuable patents for compounds with potential applications beyond COVID-19. This acquisition involves a complex stock purchase agreement valuing NDPD’s assets at over $11 million, with Bioxytran issuing shares to acquire NDPD’s common stock. The acquisition also involves goodwill and deferred tax considerations, showcasing Bioxytran’s commitment to expanding its portfolio and leveraging NDPD’s expertise for broader service offerings.
For a thorough assessment of BIXT stock, go to TipRanks’ Stock Analysis page.
